Table 1.
Demographic features of study groups.
| Study Groups | No | % | * Age (Years) | ** BMI (kg /m2) |
|---|---|---|---|---|
| 1. Healthy (total) | 51 | |||
| • Proliferative phase | 16 | 40 (30–57) | 27 (18–41) | |
| • Postmenopausal | 35 | 63 (40–85) | 26 (20–40) | |
| 2. Endometrial hyperplasia | 15 | 55 (48–72) | 36 (24–57) | |
| 3. Endometrial cancer (total) | 109 | 68 (37–96) | 30 (20–54) | |
| LGEC | 53 | 48.6 | 64 (37–89) | 32 (21–54) |
| • Endometrioid Grade 1 | 34 | 31.2 | 64 (46–89) | 33 (21–53) |
| • Endometrioid Grade 2 | 19 | 17.4 | 60 (37–78) | 30 (22–54) |
| HGEC | 56 | 51.4 | 73 (48–96) | 30 (20–43) |
| • Endometrioid Grade 3 | 12 | 11 | 68 (54–96) | 28 (24–43) |
| • Serous | 12 | 11 | 76 (64–87) | 29 (23–39) |
| • Clear cell | 10 | 9.1 | 74 (48–82) | 30 (27–39) |
| • Carcinosarcoma | 19 | 17.4 | 78 (60–89) | 26 (20–37) |
| • Dedifferentiated | 1 | 0.9 | 79 | 32 |
| • Mixed cell adenocarcinoma | 2 | 1.8 | 63 & 66 | |
| • Metastatic EC | 34 | 68 (27–96) | 28 (21–43) |
Abbreviations: Body mass index (BMI); high-grade endometrial carcinoma (HGEC); low-grade endometrial cancer (LGEC); * Data expressed as median (range). ** BMI data were available for only 161 cases.